On Friday, Shares of Ciena Corporation (NYSE:CIEN), lost -2.96% to $22.15.
Ciena, declared that François Locoh-Donou has been designated senior vice president and chief operating officer, effective November 1, 2015, reporting directly to President and CEO Gary B. Smith. Locoh-Donou has served as senior vice president of Ciena’s Global Products Group since August 2011.
In this new position, Locoh-Donou will assume responsibility for Ciena’s Global Field Organization, counting the global sales and services functions, while retaining his existing responsibility for research and development, product line administration, supply chain and network integration functions.
Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and administration of voice, video, and data traffic on communications networks worldwide.
Shares of Silver Standard Resources Inc. (USA) (NASDAQ:SSRI), inclined 4.50% to $ 6.74, during its last trading session.
Silver Standard Resources, declared that it has accomplished the underground drilling program beneath the San Miguel open pit at its Pirquitas mine in Argentina. High grade silver mineralization was intersected on all three veins explored, known as Chocaya, Oploca North and Oploca South.
Selected Drillhole Highlights:
- Mineral Resources extension drilling from underground intersected high grade mineralization on three vein structures.
- Chocaya: PUG-12 intersected 1,436 grams per tonne silver and 0.5% zinc over 3.2 meters true width.
- Oploca North: PUG-03 intersected 1,890 grams per tonne silver and 7.5% zinc over 1.9 metres true width.
- Oploca South: PUG-04 intersected 2,670 grams per tonne silver and 1.3% zinc over 0.8 metres true width.
Silver Standard Resources Inc. engages in the acquisition, exploration, development, and operation of precious metal mineral properties in the Americas. The company primarily explores for silver, gold, zinc, and lead deposits. Its principal projects comprise the Pirquitas mine compriseing of 50 semi-contiguous mineral exploration concessions covering a total area of 3,621 hectares located in the Puna de Jujeña region of northwestern Argentina in the province of Jujuy; and Marigold mine comprising about 19,560 acres situated in southeastern Humboldt County, Nevada.
At the end of Friday’s trade, Shares of Medivation Inc (NASDAQ:MDVN), lost -1.88% to $50.57.
Medivation, declared that it has effected a stock dividend on its common stock, in which each outstanding share of common stock received an additional share of common stock.
Medivation’s common stock will start trading on a post-dividend basis on the NASDAQ Global Select Market at the opening of trading recently, September 16, 2015.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
Finally, St. Jude Medical, Inc. (NYSE:STJ), ended its last trade with -2.79% loss, and closed at $67.31.
St. Jude Medical, declared the European CE Mark approval for the 27mm and 29mm Portico™ Transcatheter Aortic Valve Replacement System. The approval follows previous approvals of the 23mm and 25mm Portico valves, allowing St. Jude Medical to offer physicians an expanded range of fully repositionable, retrievable TAVR valve sizes. The Portico valve accommodates a patient’s native anatomy with diameters ranging from 19 to 27 mm.
Aortic stenosis is one of the most common forms of cardiovascular disease in the world, and develops as the aortic heart valve becomes calcified, narrowing the valve and preventing a complete opening. Over time, aortic stenosis disrupts the blood flow from the heart, which causes the heart to pump harder and results in weakening. TAVR procedures provide physicians an additional treatment option for patients with severe aortic stenosis who are considered high risk for open heart surgery.
St. Jude Medical, Inc., together with its auxiliaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm administration, cardiovascular, and atrial fibrillation therapy areas worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
